Skip to content

Genetics of Thoracic Aortic Aneurysm

TL;DR — Thoracic aortic aneurysm and dissection (TAAD) is substantially heritable: roughly 20–25% of non-syndromic probands have a first-degree relative with aortic disease, and inheritance is predominantly autosomal dominant with reduced penetrance and variable expressivity (Albornoz 2006, PMID 16996941; Biddinger 1997, PMID 9081132; Monda 2023, PMID 36832261). Causal genes fall into two mechanistic families — extracellular matrix / TGF-β signalling (FBN1, TGFBR1/2, SMAD3, TGFB2/3, LOX, COL3A1, MFAP5) and the smooth-muscle-cell contractile unit (ACTA2, MYH11, MYLK, PRKG1) — a partition that has shaped how the field thinks about aortic wall failure (Guo 2007, PMID 17994018; Zhu 2006, PMID 16444274). A ClinGen-framework expert curation of 53 candidate genes classified only 9 as definitive and 2 as strong, with 15 limited and 23 with no reported evidence, formalising the gap between "reported" and "actionable" (Renard 2018, PMID 30071989). Clinical panel yield in unselected TAAD cohorts is modest — 17.6% for variants judged causative, 35.3% including likely-causative (Poninska 2016, PMID 27146836) — yet a positive result is disproportionately consequential because it changes surgical thresholds and mandates cascade screening of relatives. The biggest open problem: 75% of familial TAAD kindreds still have no identified causative gene (Guo 2016, PMID 26838787), and gene-specific diameter thresholds rest on registry series rather than trials.

Familial clustering and heritability of non-syndromic TAAD

The genetic contribution to TAAD was first established epidemiologically, not molecularly. In a case-control study of 158 non-syndromic probands referred for thoracic aortic surgery and their 843 first-degree relatives, compared with 547 first-degree relatives of proband spouses, relatives of probands had a higher prevalence of thoracic aortic aneurysm and of sudden death; relative risks of thoracic aortic aneurysm were 1.8 in fathers, 10.9 in brothers, and 1.8 in sisters (Biddinger 1997, PMID 9081132). That study could not resolve a mode of inheritance.

A larger pedigree series of 520 patients with TAAD resolved it. Among non-Marfan patients, 21.5% showed an inherited pattern; of those familial pedigrees, 76.9% were autosomal dominant with varying penetrance and expressivity (Albornoz 2006, PMID 16996941). The same series produced the phenotypic contrasts that still frame the field:

Group n Mean age at presentation Aortic growth rate
Familial non-Marfan TAA 101 (88 pedigrees) 58.2 y 0.21 cm/yr
Sporadic TAA 369 65.7 y 0.16 cm/yr
Marfan syndrome 50 27.4 y 0.10 cm/yr

(all comparisons p < 0.01 for growth; age differences p < 0.0001; Albornoz 2006, PMID 16996941)

Familial TAAD therefore presents ~7 years earlier and grows ~30% faster than sporadic disease — an aggressiveness gradient that is the practical argument for identifying it. Aneurysms in affected relatives are not confined to the thoracic aorta: among 197 probands and affected kindred, 66.5% had thoracic aortic aneurysm, 24.9% abdominal aortic aneurysm, and 8.6% cerebral or other aneurysms; ascending disease paired most often with ascending, and descending with abdominal (Albornoz 2006, PMID 16996941).

The ~20% figure has been reproduced repeatedly. Contemporary statements put it at "up to 20%" of non-syndromic TAAD probands having a family history (Guo 2015, PMID 25557781) and "about 20–25%" of non-syndromic heritable thoracic aortic disease (HTAD) exhibiting familial aggregation (Monda 2023, PMID 36832261). Separately, up to 25% of all individuals with thoracic aortic disease are estimated to harbour an underlying Mendelian pathogenic variant (Renard 2018, PMID 30071989).

Gene table

Two mechanistic families dominate. Mutations disrupting the extracellular matrix or TGF-β signalling produce medial degeneration; mutations disrupting the smooth-muscle contractile unit (α-actin → myosin → myosin light chain kinase → PKG regulation) produce a phenotypically distinct, often earlier and less dilatation-dependent disease. The insight that contractile-unit failure alone suffices to destroy the ascending aorta came from ACTA2 and MYH11 (Guo 2007, PMID 17994018; Zhu 2006, PMID 16444274).

Gene Protein / pathway Syndromic or non-syndromic Inheritance Distinctive features Defining citation (PMID)
FBN1 Fibrillin-1; ECM microfibril, TGF-β sequestration Marfan syndrome (also non-syndromic TAAD) AD; up to 25% de novo Aortic root aneurysm + ectopia lentis are the cardinal pair; long-bone overgrowth 1852208
TGFBR1 TGF-β receptor type I; Ser/Thr kinase Loeys-Dietz syndrome type 1/2 AD Arterial tortuosity, hypertelorism, bifid uvula/cleft palate; aggressive widespread aneurysm 15731757
TGFBR2 TGF-β receptor type II Loeys-Dietz syndrome AD As TGFBR1; dissection reported at root ≤45 mm, notably in low-BSA women 15731757
SMAD3 SMAD3; canonical TGF-β transcriptional effector Aneurysms-osteoarthritis syndrome (LDS type 3) AD Early-onset osteoarthritis + osteochondritis dissecans often the presenting complaint; intracranial aneurysms 21217753 †
TGFB2 TGF-β2 ligand Syndromic TAAD within LDS spectrum AD (haploinsufficiency) Milder LDS-spectrum phenotype; paradoxical upregulation of TGF-β signalling in aortic tissue 22772368
TGFB3 TGF-β3 ligand Syndromic TAAD (LDS/Shprintzen-Goldberg overlap) AD Cleft palate, bifid uvula, skeletal overgrowth, cervical spine instability, clubfoot; mitral valve disease 25835445
ACTA2 Smooth muscle α-actin; contractile unit Non-syndromic FTAAD (± livedo, iris flocculi, moyamoya) AD Commonest non-syndromic cause; presents with dissection more often than with repaired aneurysm 17994018
MYH11 Smooth muscle myosin heavy chain Non-syndromic FTAAD + patent ductus arteriosus AD (dominant-negative) TAAD–PDA syndrome; marked aortic stiffness even in asymptomatic carriers 16444274
MYLK Myosin light chain kinase Non-syndromic familial aortic dissection AD (loss of function) Dissection with little or no antecedent aortic enlargement — diameter-based surveillance fails 21055718
PRKG1 Type I cGMP-dependent protein kinase (PKG-1) Non-syndromic FTAAD AD (gain of function) Recurrent p.Arg177Gln; 63% present with acute dissection, mean age 31 y 23910461
LOX Lysyl oxidase; collagen/elastin cross-linking Non-syndromic FTAAD AD Fusiform root + ascending enlargement leading to ascending dissection 26838787
COL3A1 Type III procollagen Vascular Ehlers-Danlos syndrome AD Arterial, bowel and uterine rupture; median survival 48 y; fragility without much dilatation 10706896 ‡
FLNA Filamin A; actin cross-linking X-linked periventricular nodular heterotopia with vascular disease X-linked dominant Seizures + PVNH; PDA, dystrophic valve disease, aortic dissection; high male perinatal lethality 26471271 ‡
MFAP5 MAGP-2; microfibril-associated glycoprotein Non-syndromic FTAAD AD (haploinsufficiency) Interacts with elastin fibres and the microfibrillar network 25434006
FOXE3 Forkhead transcription factor Non-syndromic FTAAD AD Reduced aortic SMC number in development; increased SMC apoptosis under raised pressure 26854927
MAT2A Methionine adenosyltransferase IIα Non-syndromic FTAAD, variably with bicuspid aortic valve AD Rare; co-segregates with BAV in the index kindred 25557781
NOTCH1 NOTCH1 receptor; represses RUNX2 Bicuspid aortic valve ± calcification ± TAA AD Developmental valve defect plus later de-repression of calcification 16025100
SLC2A10 GLUT10 facilitative glucose transporter Arterial tortuosity syndrome Autosomal recessive Generalised tortuosity, elongation, stenosis and aneurysm of major arteries; TGF-β pathway upregulation 16550171

† Gene discovery paper (van de Laar 2011, Nat Genet; delineated the aneurysms-osteoarthritis syndrome — aneurysms, dissections and tortuosity throughout the arterial tree with early-onset osteoarthritis — and mapped it to SMAD3). The row's phenotypic detail (osteochondritis dissecans as presenting complaint, intracranial aneurysms) comes from the same group's phenotypic-spectrum series (45 patients, 8 families, 8 mutations; van de Laar 2012, PMID 22167769). Both were verified in this session. ‡ These citations are defining clinical/molecular series rather than the original gene-mapping report.

Note on breadth: this table lists genes for which a primary paper was verified in this session. It is not the complete HTAD panel — several genes on commercial panels (e.g. EFEMP2, SKI, SLC2A10-adjacent loci, BGN) are omitted because no primary citation was retrieved here.

Gene-validity curation: definitive vs limited evidence

The proliferation of "TAAD genes" outran the evidence, and panels were being sold containing genes whose disease association was a single small pedigree. A ClinGen-framework expert curation resolved this. Fifty-three candidate genes were assessed by pre-defined curator–expert pairs and adjudicated by an expert panel (Renard 2018, PMID 30071989):

ClinGen classification Number of genes
Definitive 9
Strong 2
Moderate 4
Limited 15
No reported evidence 23

The 11 genes in the definitive-plus-strong groups were designated "HTAAD genes" (category A) — genes for which a positive result should trigger routine aortic surveillance, intervention, and family cascade screening. Genes were further stratified by the severity and progression risk of the associated aortic disease: 8 genes classified as unlikely to be progressive (category B) and 4 as low risk (category C) (Renard 2018, PMID 30071989).

The per-gene assignments (verified from the full text in this session): definitive — ACTA2, COL3A1, FBN1, MYH11, MYLK, SMAD3, TGFB2, TGFBR1, TGFBR2; strong — LOX and PRKG1 (more recently reported, but carried by high-LOD segregation and mouse-model data respectively). These 11 are category A. Category B — EFEMP2 (moderate) plus ELN, FBN2, FLNA, NOTCH1, SLC2A10, SMAD4 and SKI (limited): genes in which aortic enlargement occurs without evidence of progression to dissection. Category C — COL4A5, PKD1, PKD2, CBS: conditions diagnosed on renal or metabolic features, with variants best regarded as low-risk "risk alleles" for thoracic aortic disease. Seven recently reported genes (BGN, FOXE3, HCN4, MAT2A, MFAP5, SMAD2, TGFB3) were parked in a separate "uncertain" category pending replication, and B3GAT3 was downgraded by the expert panel from limited to no evidence (Renard 2018, PMID 30071989). Note the corollary for this page's gene table: NOTCH1, SLC2A10 and FLNA (category B) and MFAP5, FOXE3, MAT2A and TGFB3 (uncertain) sit outside the actionable category A set.

The practical consequence is that a variant in a limited-evidence gene is not a clinical result. Reporting one as actionable creates false reassurance in variant-negative relatives and unjustified surgery in variant-positive ones.

Genotype-stratified surgical thresholds

The central clinical payoff of genetic diagnosis is that the diameter at which a given aorta is dangerous depends on which gene is broken. Three lines of evidence establish this.

TGFBR1/TGFBR2 (Montalcino Aortic Consortium). In 441 patients from 228 families (176 TGFBR1, 265 TGFBR2) across 15 specialist centres, survival was 80% at 60 years, with 23% experiencing aortic dissection and 18% undergoing preventive aortic surgery. TGFBR1 and TGFBR2 carriers had the same prevalence of systemic features and the same global survival; TGFBR1 males had greater aortic risk than females, while TGFBR2 males and females had similar risk. Critically, aortic root diameter at or before type A dissection tended to be smaller in TGFBR2 carriers, and was ≤45 mm in 6 women with TGFBR2 mutations who had marked systemic features and low body surface area. The registry's conclusion — preventive surgery at 45 mm, lowered toward 40 mm in low-BSA women with TGFBR2 mutations and severe extra-aortic features — is the clearest published example of a gene-and-sex-stratified threshold (Jondeau 2016, PMID 27879313). Aortic dissection complicated 1.6% of pregnancies in this cohort.

ACTA2. In 277 individuals carrying 41 different ACTA2 mutations, aortic events occurred in 48%, and the vast majority presented with dissection (88%) rather than with an aneurysm found in time to repair — only 12% of aortic events were repair of an ascending aneurysm. Mortality with dissection was 25%. Type A dissections outnumbered type B (54% vs 21%), but type B occurred at a younger median age (27 y vs 36 y). Cumulative risk of an aortic event by age 85 was 0.76 (95% CI 0.64–0.86). Within the gene, mutations disrupting p.R179 and p.R258 carried significantly increased risk, while p.R185Q and p.R118Q carried significantly lower risk than other mutations (Regalado 2015, PMID 25759435). ACTA2 therefore demonstrates that stratification is needed not just between genes but within a gene, at codon resolution.

MYLK. The two families in which MYLK variants segregated (p.R1480X and p.S1759P; maximum LOD 2.1, p = 0.0009) shared "a similar phenotype characterized by presentation with an acute aortic dissection with little to no enlargement of the aorta" (Wang 2010, PMID 21055718). This is the sharpest challenge to diameter-based management that exists in the field: for MYLK carriers, the surveillance variable used for everyone else does not move before the event.

That the ACTA2 lifetime aortic-event risk is 76% rather than ~100% is itself informative — it implies additional genetic or environmental modifiers determine expression even in confirmed carriers (Regalado 2015, PMID 25759435).

See risk stratification and size thresholds for the diameter evidence base and guidelines for the class/level-of-evidence framing of gene-specific thresholds.

Genetic testing strategy

Who to test. Genetic testing confirms the aetiological diagnosis of HTAD — particularly in patients with a significant family history — and guides family screening; because the different HTAD conditions differ substantially in natural history and treatment strategy, the genetic diagnosis materially changes management (Monda 2023, PMID 36832261). Careful clinical evaluation of the proband and first-degree relatives is required first, in order to distinguish familial from sporadic cases (Monda 2023, PMID 36832261). Screening of first-order relatives of any TAA proband has been argued to be essential on natural-history grounds alone (Albornoz 2006, PMID 16996941).

For Marfan syndrome specifically, genetic testing is not always required for diagnosis under the Ghent II nosology, but it distinguishes MFS from other HTAD syndromes that present with overlapping skeletal features (Milewicz 2021, PMID 34475413) — see syndromic aortopathies.

Panel vs exome. Both are in use. A study of 51 unrelated TAAD patients used whole-exome sequencing or a large sequencing panel and analysed rare variants in 10 established TAA-associated genes (Poninska 2016, PMID 27146836). Panel-based testing constrains the interpretive burden to genes with established validity; exome/genome shifts the burden to variant filtering and raises the incidental-finding rate.

Diagnostic yield. In that 51-patient cohort, 22 rare variants were found in 21 patients; 6 (27.3%) had been previously reported and 16 were novel. Applying segregation data, functional analysis and in-silico prediction, 3 novel variants were judged causative and 9 likely causative, with 4 classed as unknown significance or likely benign. Yield was therefore:

Definition of positive Probands positive Yield
Causative variants only 9 / 51 17.6%
Causative + likely causative 18 / 51 35.3%

Genotype-positive probands had significantly shorter mean event-free survival (41 y, CI 35–46) than variant-negative probands (51 y, CI 45–57; p = 0.0083), and probands with defects in TGF-β signalling had the shortest (37 y, CI 27–47; p = 0.0033 vs reference) (Poninska 2016, PMID 27146836). A positive genotype is thus prognostic, not merely diagnostic.

Variant interpretation pitfalls.

  1. Gene validity, not just variant pathogenicity. 15 of 53 curated genes had only limited evidence and 23 had none (Renard 2018, PMID 30071989); a "pathogenic-looking" variant in such a gene should not drive surgery.
  2. Novel-variant dominance. 16 of 22 rare variants in one clinical cohort were novel (Poninska 2016, PMID 27146836) — meaning most positive results require de-novo interpretation rather than database lookup, with segregation analysis carrying much of the weight.
  3. Reduced penetrance. Familial TAAD is autosomal dominant with "varying degrees of penetrance and expressivity" (Albornoz 2006, PMID 16996941), and even ACTA2 carriers reach only 76% cumulative event risk by 85 (Regalado 2015, PMID 25759435). An unaffected middle-aged carrier does not refute pathogenicity.
  4. Intragenic heterogeneity. Risk varies by codon within ACTA2 (Regalado 2015, PMID 25759435); "ACTA2-positive" is not one prognosis.
  5. Genotype does not predict complication type in every gene. In vascular EDS, the types of complications were not associated with specific COL3A1 mutations (Pepin 2000, PMID 10706896).
  6. Phenocopy risk. LDS was originally recognised partly by screening a cohort of patients labelled vascular EDS who lacked type III collagen abnormalities — 12 of 40 such probands carried TGFBR1/TGFBR2 mutations (Loeys 2006, PMID 16928994). Clinical labels mislead; the genotype reassigns them.

Cascade family screening. The purpose of establishing a molecular diagnosis in the proband is to convert relatives from "screen everyone by imaging indefinitely" to "test once, then image only carriers." Renard's definition of an actionable HTAAD gene is explicitly one whose identification triggers routine aortic surveillance, intervention, and family cascade screening (Renard 2018, PMID 30071989). Where the proband is variant-negative, imaging-based screening of first-degree relatives remains necessary because absence of an identified variant does not exclude heritable disease — 75% of familial TAAD kindreds have no known causative gene (Guo 2016, PMID 26838787).

Practical caution for X-linked FLNA disease: a median diagnostic latency of 17–20 years between seizure onset and genetic diagnosis was documented in a 47-patient FLNA cohort, "intensely delaying appropriate medical surveillance for potentially life threatening cardiovascular complications" (Lange 2015, PMID 26471271). The aortic risk in this gene is routinely missed because the presenting specialty is neurology.

What remains ungenotyped

Mutations in known genes account for approximately 25% of families with familial TAAD; the causative gene remains unknown in 75% (Guo 2016, PMID 26838787). Gene discovery has proceeded by exome sequencing of large multiplex kindreds followed by targeted sequencing of several hundred additional probands — the template used for LOX (410 additional probands; PMID 26838787), MYLK (193 probands; PMID 21055718), MFAP5 (403 probands; PMID 25434006) and TGFB3 (470 index cases; PMID 25835445). Each such effort now returns a smaller number of families, implying the remaining architecture is not a short list of further large-effect Mendelian genes. See omics and emerging science.

Open questions

  • Are gene-specific surgical thresholds correct, or merely plausible? The 45 mm / 40 mm TGFBR2 thresholds derive from retrospective registry observation of 6 women who dissected at ≤45 mm, not from a prospective comparison (Jondeau 2016, PMID 27879313). No trial has tested whether operating earlier in genotype-defined subgroups improves survival.
  • What determines penetrance in confirmed carriers? Lifetime aortic-event risk in ACTA2 carriers is 76%, not ~100%, implying unidentified genetic or environmental modifiers (Regalado 2015, PMID 25759435). The modifiers are unknown.
  • How should MYLK-type disease be surveilled at all? Carriers dissect "with little to no enlargement of the aorta" (Wang 2010, PMID 21055718), so diameter surveillance is structurally uninformative. No validated alternative surveillance variable exists for this phenotype.
  • What explains the 75% of familial TAAD with no identified gene? (Guo 2016, PMID 26838787). Whether this is many additional rare Mendelian genes, oligogenic architecture, non-coding variation, or polygenic burden is unresolved.
  • Is the TGF-β signature cause or compensation? TGFB2 haploinsufficiency — a loss-of-function ligand mutation — produces increased canonical and non-canonical TGF-β signalling in aortic tissue, and Tgfb2+/− mice worsen the Fbn1 phenotype in association with high TGF-β1 expression, suggesting compensatory autocrine/paracrine events drive the pathology (Lindsay 2012, PMID 22772368). Whether the elevated signalling is pathogenic or protective remains contested — see pathophysiology.
  • How should limited-evidence-gene variants be reported to patients? 15 limited and 23 no-evidence genes were identified in curation (Renard 2018, PMID 30071989), yet such genes persist on commercial panels; the harm/benefit balance of reporting them has not been measured.

References

  1. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352:337-9. PMID 1852208
  2. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37:275-81. PMID 15731757
  3. Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355:788-98. PMID 16928994
  4. Zhu L, Vranckx R, Khau Van Kien P, et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet. 2006;38:343-9. PMID 16444274
  5. Guo DC, Pannu H, Tran-Fadulu V, et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet. 2007;39:1488-93. PMID 17994018
  6. Wang L, Guo DC, Cao J, et al. Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet. 2010;87:701-7. PMID 21055718
  7. van de Laar IMBH, van der Linde D, Oei EHG, et al. Phenotypic spectrum of the SMAD3-related aneurysms-osteoarthritis syndrome. J Med Genet. 2012;49:47-57. PMID 22167769
  8. Lindsay ME, Schepers D, Bolar NA, et al. Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm. Nat Genet. 2012;44:922-7. PMID 22772368
  9. Guo DC, Regalado E, Casteel DE, et al. Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am J Hum Genet. 2013;93:398-404. PMID 23910461
  10. Barbier M, Gross MS, Aubart M, et al. MFAP5 loss-of-function mutations underscore the involvement of matrix alteration in the pathogenesis of familial thoracic aortic aneurysms and dissections. Am J Hum Genet. 2014;95:736-43. PMID 25434006
  11. Guo DC, Gong L, Regalado ES, et al. MAT2A mutations predispose individuals to thoracic aortic aneurysms. Am J Hum Genet. 2015;96:170-7. PMID 25557781
  12. Bertoli-Avella AM, Gillis E, Morisaki H, et al. Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol. 2015;65:1324-1336. PMID 25835445
  13. Regalado ES, Guo DC, Prakash SK, et al. Aortic disease presentation and outcome associated with ACTA2 mutations. Circ Cardiovasc Genet. 2015;8:457-64. PMID 25759435
  14. Guo DC, Regalado ES, Gong L, et al. LOX mutations predispose to thoracic aortic aneurysms and dissections. Circ Res. 2016;118:928-34. PMID 26838787
  15. Kuang SQ, Medina-Martinez O, Guo DC, et al. FOXE3 mutations predispose to thoracic aortic aneurysms and dissections. J Clin Invest. 2016;126:948-61. PMID 26854927
  16. Coucke PJ, Willaert A, Wessels MW, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006;38:452-7. PMID 16550171
  17. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005;437:270-4. PMID 16025100
  18. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342:673-80. PMID 10706896
  19. Lange M, Kasper B, Bohring A, et al. 47 patients with FLNA associated periventricular nodular heterotopia. Orphanet J Rare Dis. 2015;10:134. PMID 26471271
  20. Renard M, Francis C, Ghosh R, et al. Clinical validity of genes for heritable thoracic aortic aneurysm and dissection. J Am Coll Cardiol. 2018;72:605-615. PMID 30071989
  21. Biddinger A, Rocklin M, Coselli J, Milewicz DM. Familial thoracic aortic dilatations and dissections: a case control study. J Vasc Surg. 1997;25:506-11. PMID 9081132
  22. Albornoz G, Coady MA, Roberts M, et al. Familial thoracic aortic aneurysms and dissections — incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg. 2006;82:1400-5. PMID 16996941
  23. Jondeau G, Ropers J, Regalado E, et al. International registry of patients carrying TGFBR1 or TGFBR2 mutations: results of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet. 2016;9:548-558. PMID 27879313
  24. Poninska JK, Bilinska ZT, Franaszczyk M, et al. Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations. J Transl Med. 2016;14:115. PMID 27146836
  25. Monda E, Lioncino M, Verrillo F, et al. The role of genetic testing in patients with heritable thoracic aortic diseases. Diagnostics (Basel). 2023;13:772. PMID 36832261
  26. Milewicz DM, Braverman AC, De Backer J, et al. Marfan syndrome. Nat Rev Dis Primers. 2021;7:64. PMID 34475413
  27. van de Laar IM, Oldenburg RA, Pals G, et al. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011;43:121-6. PMID 21217753